Home » Stocks » CRIS

Curis, Inc. (CRIS)

Stock Price: $9.47 USD 0.34 (3.72%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $9.54 +0.07 (0.74%) Mar 5, 7:44 PM
Market Cap 732.15M
Revenue (ttm) 11.10M
Net Income (ttm) -31.00M
Shares Out 54.55M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $9.47
Previous Close $9.13
Change ($) 0.34
Change (%) 3.72%
Day's Open 9.07
Day's Range 8.25 - 9.54
Day's Volume 1,881,160
52-Week Range 0.62 - 13.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 weeks ago

LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ann...

Seeking Alpha - 1 month ago

Quick overview of Curis and stock price history. Review on the potential for therapies that target the immune system checkpoint regulator “VISTA” (V-domain immunoglobulin (Ig) suppressor of T ...

PRNewsWire - 1 month ago

LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...

Seeking Alpha - 2 months ago

Overview of Curis, including key partnerships, balance sheet, and recent stock price. Review of Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes and Acute Myeloid Leukemia. Patient need, curr...

OTC PR Wire - 2 months ago

Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)

Other stocks mentioned: BLNK
Zacks Investment Research - 2 months ago

Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

24/7 Wall Street - 2 months ago

Curis Inc. (NASDAQ: CRIS) shares are on the run again.

PRNewsWire - 2 months ago

LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today annou...

Zacks Investment Research - 2 months ago

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma....

Pulse2 - 2 months ago

The stock price of Curis, Inc. (NASDAQ: CRIS) increased by 354.86% as it went from a previous close of $1.44 to $6.55 per share today. This is why it happened.

Business Insider - 2 months ago

Curis, Inc. staged an eye-popping rally on Tuesday after it released positive preliminary data related to its phase one trial of CA-4948, a small molecule inhibitor that is being tested in pat...

The Motley Fool - 2 months ago

Further gains for the top stock market came from big movers.

Other stocks mentioned: SFIX
Benzinga - 2 months ago

Curis, Inc. (NASDAQ: CRIS) shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myel...

InvestorPlace - 2 months ago

Curis (CRIS) stock is taking off on Tuesday following news of positive preliminary data from a Phase 1 clinical trial for its leukemia drug. The post CRIS Stock News: Why Biotech Stock Play Cu...

24/7 Wall Street - 2 months ago

After Curis Inc. (NASDAQ: CRIS) announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), its sh...

Market Watch - 2 months ago

Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study...

PRNewsWire - 2 months ago

LEXINGTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...

Seeking Alpha - 3 months ago

Curis, Inc. (CRIS) CEO Jim Dentzer on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Curis, Inc. (CRIS) CEO Jim Dentzer On Q3 2020 Results - Quick Version Earnings Call Transcript

Benzinga - 3 months ago

Shares of Curis (NASDAQ:CRIS) fell 0.88% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 42.11% year over year to ($0.11), which b...

PRNewsWire - 4 months ago

LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...

PRNewsWire - 4 months ago

LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...

PRNewsWire - 4 months ago

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today hig...

PRNewsWire - 4 months ago

LEXINGTON, Mass., Oct. 14, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ann...

Seeking Alpha - 7 months ago

Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 8 months ago

The Only Way To Play Curis

PRNewsWire - 8 months ago

LEXINGTON, Mass., June 11, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ann...

Benzinga - 8 months ago

Shares of nano-cap biopharma Curis, Inc. (NASDAQ: CRIS) are on a strong two-day run that has lifted the equity from penny stock territory.

24/7 Wall Street - 8 months ago

Curis Inc. (NASDAQ: CRIS) shares jumped on Wednesday after the company announced that the U.S.

Seeking Alpha - 9 months ago

Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Curis' (CRIS) CEO Jim Dentzer on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2018 Results - Earnings Call Transcript

Benzinga - 1 year ago

Thinly traded Curis, Inc. shares weremoving notably higher Monday on roughly 35 times their average volume.

24/7 Wall Street - 1 year ago

Curis Inc. shares made a massive gain to start out the week.

Market Watch - 1 year ago

Shares of Curis, Inc. rocketed 93% in very active premarket trade Monday.

About CRIS

Curis, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 1, 2000
CEO
James Dentzer
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
CRIS
Full Company Profile

Financial Performance

In 2019, Curis, Inc.'s revenue was $10.00 million, a decrease of -4.07% compared to the previous year's $10.43 million. Losses were -$32.14 million, -1.33% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Curis, Inc. stock is "Buy." The 12-month stock price forecast is 15.75, which is an increase of 66.31% from the latest price.

Price Target
$15.75
(66.31% upside)
Analyst Consensus: Buy